ALX Oncology Holdings Inc. (ALXO): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALXO Stock Price Chart Interactive Chart >
ALXO Price/Volume Stats
|Current price||$59.66||52-week high||$117.45|
|Prev. close||$61.02||52-week low||$28.01|
|Day high||$61.18||Avg. volume||219,429|
|50-day MA||$60.60||Dividend yield||N/A|
|200-day MA||$63.45||Market Cap||2.40B|
ALX Oncology Holdings Inc. (ALXO) Company Bio
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia on April 1, 2020 and is headquartered in Burlingame, CA.
ALXO Latest News Stream
|Loading, please wait...|
ALXO Latest Social Stream
View Full ALXO Social Stream
Latest ALXO News From Around the Web
Below are the latest news stories about Alx Oncology Holdings Inc that investors may wish to consider to help them evaluate ALXO as an investment opportunity.
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer
Randomized Phase 2/3 Study is Planned Based on Promising Results from the ASPEN-01 Phase 1b Trial in Gastric Cancer PatientsBURLINGAME, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- ALX Oncology (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company to evaluate the combination of ALX148, a next generation CD47 blocker, and CY
The following slide deck was published by ALX Oncology Holdings Inc. in conjunction with this event....
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
- The first of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated BURLINGAME, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, in partnership with Merck, known as MSD outside the United States and Canada, today announced the first patient has been dosed in the Phase 2 ASPEN-03 study evaluating the combination of ALX148, a next generation CD47 blocker, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with advanced head and neck squamous cell carcinoma (“HNSCC”). ASPEN-03 (NCT04675294) is an open-label, randomized phase 2 multi-center study of the anti-tumor eff...
ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer
Updated results will be presented from ASPEN-01, the ongoing Phase 1b Study of ALX148 in combination trastuzumab, ramucirumab and paclitaxel in patients with gastric or gastroesophageal junction cancerBURLINGAME, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that our Phase 1b study of ALX148 in patients with advanced gastric or gastroesophageal junction cancer has been selected for a short oral presentation at the ESMO 23rd World Congress on Gastrointestinal Cancer to be held virtually from June 30 – July 3, 2021. Oral Presentation Information Title: ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combinat...
ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148
The post-grant review period for U.S. Patent 10,696,730 covering the composition of matter of ALX148 ended on March 30, 2021. This patent provides coverage of ALX148 until at least 2036, not including term adjustments or extensions. BURLINGAME, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announces that the post-grant review period for granted U.S. Patent No. 10,696,730 ended on March 30, 2021. This patent covers the lead product candidate ALX148, a next generation CD47-blocking therapeutic that combines a high-affinity signal regulatory protein-alpha (“SIRP“) CD47-binding domain fused with an inactivated, proprietary Fc domain...
ALXO Price Returns